C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma-Reference-Cited by-同舟云学术

C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Published:2024-05-28 Issue:4 Volume:19 Page:635-644
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Uchimoto Taizo,Matsuda Takuya,Komura Kazumasa,Fukuokaya Wataru,Adachi Takahiro,Hirasawa Yosuke,Hashimoto Takeshi,Yoshizawa Atsuhiko,Saruta Masanobu,Hashimoto Mamoru,Higashio Takuya,Tsuchida Shuya,Nishimura Kazuki,Tsujino Takuya,Nakamura Ko,Fukushima Tatsuo,Nishio Kyosuke,Yamamoto Shutaro,Iwatani Kosuke,Urabe Fumihiko,Mori Keiichiro,Yanagisawa Takafumi,Tsuduki Shunsuke,Takahara Kiyoshi,Inamoto Teruo,Miki Jun,Fujita Kazutoshi,Kimura Takahiro,Ohno Yoshio,Shiroki Ryoichi,Uemura Hirotsugu,Azuma Haruhito

Funder

Japan Society for the Promotion of Science

Kenzo Suzuki Foundation

SGH Foundation

Naito Foundation

Cancer Translational Research Foundation of Japanese Urological Association

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11523-024-01068-7.pdf

Reference38 articles.

1. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.

2. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.

3. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.

4. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338–48.

5. Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–35.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan;Cancers;2024-07-25